Sterling Capital Management LLC raised its stake in shares of Edwards Lifesciences Corp (NYSE:EW) by 6.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,351 shares of the medical research company’s stock after buying an additional 1,471 shares during the quarter. Sterling Capital Management LLC’s holdings in Edwards Lifesciences were worth $2,771,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Koch Industries Inc. raised its stake in shares of Edwards Lifesciences by 28,363.1% in the second quarter. Koch Industries Inc. now owns 1,397,254 shares of the medical research company’s stock worth $1,386,000 after purchasing an additional 1,392,345 shares during the last quarter. Artisan Partners Limited Partnership raised its stake in shares of Edwards Lifesciences by 90.6% in the second quarter. Artisan Partners Limited Partnership now owns 1,278,532 shares of the medical research company’s stock worth $151,174,000 after purchasing an additional 607,784 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Edwards Lifesciences by 1,135.0% in the third quarter. Janus Henderson Group PLC now owns 619,703 shares of the medical research company’s stock worth $67,739,000 after purchasing an additional 569,525 shares during the last quarter. Old Mutual Global Investors UK Ltd. raised its stake in shares of Edwards Lifesciences by 83.0% in the third quarter. Old Mutual Global Investors UK Ltd. now owns 1,100,885 shares of the medical research company’s stock worth $120,337,000 after purchasing an additional 499,436 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Edwards Lifesciences by 20.2% in the third quarter. Wells Fargo & Company MN now owns 2,548,282 shares of the medical research company’s stock worth $278,553,000 after purchasing an additional 429,022 shares during the last quarter. Institutional investors and hedge funds own 81.82% of the company’s stock.

Several research analysts have recently weighed in on EW shares. SunTrust Banks set a $124.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Canaccord Genuity reiterated a “buy” rating and set a $135.00 price objective (down previously from $155.00) on shares of Edwards Lifesciences in a research report on Wednesday, October 25th. Cowen reiterated a “buy” rating and set a $135.00 price objective on shares of Edwards Lifesciences in a research report on Thursday, October 12th. Royal Bank of Canada reiterated a “buy” rating and set a $130.00 price objective on shares of Edwards Lifesciences in a research report on Friday, September 1st. Finally, BMO Capital Markets reiterated a “buy” rating and set a $132.00 price objective on shares of Edwards Lifesciences in a research report on Friday, September 1st. Six equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $126.43.

Shares of Edwards Lifesciences Corp (NYSE:EW) opened at $114.22 on Friday. Edwards Lifesciences Corp has a fifty-two week low of $86.55 and a fifty-two week high of $121.45. The company has a current ratio of 3.49, a quick ratio of 2.76 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $24,175.47, a PE ratio of 31.65, a price-to-earnings-growth ratio of 2.04 and a beta of 0.51.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by ($0.02). The company had revenue of $821.50 million for the quarter, compared to the consensus estimate of $833.85 million. Edwards Lifesciences had a net margin of 20.71% and a return on equity of 22.36%. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.68 EPS. equities research analysts expect that Edwards Lifesciences Corp will post 3.76 EPS for the current fiscal year.

Edwards Lifesciences declared that its board has authorized a share repurchase program on Thursday, December 7th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical research company to reacquire shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

In other news, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $100.93, for a total value of $3,320,597.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Larry L. Wood sold 18,960 shares of the company’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $108.54, for a total value of $2,057,918.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 139,580 shares of company stock valued at $14,887,125. Corporate insiders own 2.13% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Sterling Capital Management LLC Buys 1,471 Shares of Edwards Lifesciences Corp (EW)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/12/17/sterling-capital-management-llc-buys-1471-shares-of-edwards-lifesciences-corp-ew.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related stocks with our FREE daily email newsletter.